Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)											1 Months Ended		3 Months Ended		9 Months Ended
Liquidity (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 05, 2017	Jun. 21, 2017	Jun. 21, 2017	Jun. 16, 2017	Apr. 18, 2017	Mar. 22, 2017	Feb. 08, 2017	Jan. 25, 2017	Jan. 06, 2017	Apr. 18, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jul. 07, 2017	Sep. 28, 2016	Dec. 31, 2015	Oct. 31, 2014
Cash and cash equivalents												$ 602,000	$ 11,703,000	$ 1,693,000	$ 11,703,000	$ 1,693,000			$ 8,310,000
Accounts receivable, net												2,209,000	2,803,000		2,803,000
Total current assets												4,240,000	15,773,000		15,773,000
Total current liabilities												16,241,000	8,302,000		8,302,000
Net income (loss)													3,316,000	$ 7,493,000	7,208,000	14,613,000
Net cash used in operating activities															12,884,000	$ 6,617,000
Proceeds from issuance of sale of equity															$ 27,900,000
Number of common stock shares issued				9,900,000
Warrant exercise price		$ 1.25
Warrant term		3 years													5 years
Gross proceeds from equity offerings	$ 960,000														$ 27,900,000
Underwriters over-allotment option to purchase common stock	875,000				1,875,000
Proceeds from exercise of warrants															$ 900,000
Warrants exercised															747,800
SCM Specialty Finance Opportunities Fund, L.P [Member]
Line of credit																		$ 1,200,000
Senior Secured Convertible Note [Member]
Debt conversion, converted instrument, shares issued											3,795,429
RedPath Note [Member]
Debt instrument, face amount												9,340,000								$ 1,070,000
Repayments of debt												$ 1,330,000
RedPath Note [Member] \| Senior Secured Convertible Note [Member]
Debt instrument, face amount													5,320,000		$ 5,320,000
RedPath Note [Member] \| Senior Secured Non-Convertible Note [Member]
Debt instrument, face amount						$ 3,550,000					$ 3,550,000		$ 3,550,000		3,550,000
Debt conversion, converted instrument, shares issued						3,795,429
RedPath Note [Member] \| Investor [Member]
Business combination cash acquired							$ 8,870,000
June 21, 2017 [Member]
Proceeds from exercise of warrants															6,200,000
October 31, 2017 [Member]
Proceeds from exercise of warrants															$ 1,200,000
Warrants exercised															925,000
October 12, 2017 [Member]
Warrant exercise price													$ 1.25		$ 1.25
Warrants exercised															4,000,000
Base Warrants [Member]
Number of common stock shares issued				12,500,000
Warrants description				Each Base Warrant upon exercise at a price of $1.25 will result in the issuance of one share of common stock to the holder. A public trading market for the Base Warrants was established on July 5, 2017 on the OTC market under the trading symbol IDGGW.
Gross proceeds from equity offerings				$ 13,700,000
Underwriters over-allotment option to purchase common stock					1,875,000
Underwriter Warrants[Member]
Number of common stock shares issued			575,000
Warrant to purchase shares of common stock			1,875,000	1,875,000
Warrant exercise price			$ 0.01	$ 0.01									1.32		$ 1.32
Prefunded Warrants [Member]
Number of common stock shares issued				2,600,000
Warrant to purchase shares of common stock			2,600,000	2,600,000													2,600,000
Warrant exercise price			$ 1.09	$ 1.09	$ 1.09								0.01		0.01		$ 0.01
Gross proceeds from equity offerings				$ 12,300,000
Second Registered Direct Offering [Member]
Proceeds from issuance of sale of equity										$ 4,200,000
Number of common stock shares issued										630,000
Common stock issued price per share										$ 6.81
Third Registered Direct Offering [Member]
Number of common stock shares issued									855,000
Common stock issued price per share									$ 4.69
Warrant to purchase shares of common stock									855,000
Warrant exercise price									$ 4.69
Warrant term									5 years
Third Registered Direct Offering and Private Placement [Member]
Proceeds from issuance of sale of equity									$ 4,000,000
Settlement of obligation									$ 1,000,000
Confidentially Marketed Public Offering [Member]
Proceeds from issuance of sale of equity								$ 3,900,000
Number of common stock shares issued								1,200,000
Common stock issued price per share								$ 3.00
Percentage of additional option granted for underwriters								9.00%
Public Offering [Member] \| Base Warrants [Member]
Number of common stock shares issued				9,900,000
Common stock issued price per share			$ 1.10	$ 1.10
Private Placement [Member] \| October 12, 2017 [Member]
Warrant exercise price													$ 1.80		$ 1.80
Proceeds from exercise of warrants															$ 5,000,000
Warrants exercised															3,200,000